179 related articles for article (PubMed ID: 24813344)
1. Definition of biochemical success following primary whole gland prostate cryoablation.
Levy DA; Ross AE; ElShafei A; Krishnan N; Hatem A; Jones JS
J Urol; 2014 Nov; 192(5):1380-4. PubMed ID: 24813344
[TBL] [Abstract][Full Text] [Related]
2. Predictors of prostate-specific antigen biochemical recurrence in patients undergoing primary whole-gland prostate cryoablation.
Liu YY; Chiang PH; Chuang YC; Lee WC; Cheng YT; Wang HJ
Ann Surg Oncol; 2015 May; 22(5):1612-7. PubMed ID: 25287436
[TBL] [Abstract][Full Text] [Related]
3. Five-Year Biochemical Progression-Free Survival Following Salvage Whole-Gland Prostate Cryoablation: Defining Success with Nadir Prostate-Specific Antigen.
Kovac E; ElShafei A; Tay KJ; Mendez M; Polascik TJ; Jones JS
J Endourol; 2016 Jun; 30(6):624-31. PubMed ID: 26915721
[TBL] [Abstract][Full Text] [Related]
4. Primary cryoablation nadir prostate specific antigen and biochemical failure.
Levy DA; Pisters LL; Jones JS
J Urol; 2009 Sep; 182(3):931-7. PubMed ID: 19616226
[TBL] [Abstract][Full Text] [Related]
5. Whole gland primary prostate cryoablation: initial results from the cryo on-line data registry.
Jones JS; Rewcastle JC; Donnelly BJ; Lugnani FM; Pisters LL; Katz AE
J Urol; 2008 Aug; 180(2):554-8. PubMed ID: 18550117
[TBL] [Abstract][Full Text] [Related]
6. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life.
Hubosky SG; Fabrizio MD; Schellhammer PF; Barone BB; Tepera CM; Given RW
J Endourol; 2007 Dec; 21(12):1521-31. PubMed ID: 18186694
[TBL] [Abstract][Full Text] [Related]
7. Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry.
Dhar N; Ward JF; Cher ML; Jones JS
BJU Int; 2011 Aug; 108(4):508-12. PubMed ID: 21722288
[TBL] [Abstract][Full Text] [Related]
8. A pretreatment nomogram for prediction of biochemical failure after primary cryoablation of the prostate.
Elshafei A; Kovac E; Dhar N; Levy D; Polascik T; Mouraviev V; Yu C; Jones JS
Prostate; 2015 Sep; 75(13):1447-53. PubMed ID: 26172607
[TBL] [Abstract][Full Text] [Related]
9. Prostate Specific Antigen Nadir of 0.1 or Less Is a Predictor of Treatment Success in Men Undergoing Salvage Whole Prostate Gland Cryoablation.
Nyame YA; Elshafei A; Greene DJ; Arora HC; Given RW; Tay KJ; Polascik TJ; Ross AE; Mouraviev VB; Lugnani F; Jones JS
J Endourol; 2017 May; 31(5):497-501. PubMed ID: 28437170
[TBL] [Abstract][Full Text] [Related]
10. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
11. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome.
Ng CK; Moussa M; Downey DB; Chin JL
J Urol; 2007 Oct; 178(4 Pt 1):1253-7; discussion 1257. PubMed ID: 17698104
[TBL] [Abstract][Full Text] [Related]
12. Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years.
Oishi M; Gill IS; Tafuri A; Shakir A; Cacciamani GE; Iwata T; Iwata A; Ashrafi A; Park D; Cai J; Desai M; Ukimura O; Bahn DK; Abreu AL
J Urol; 2019 Dec; 202(6):1188-1198. PubMed ID: 31347953
[TBL] [Abstract][Full Text] [Related]
13. Impact of disease burden on cryoablation prostate-specific antigen outcomes.
Levy DA; Li J; Jones S
Urology; 2010 Feb; 75(2):478-81. PubMed ID: 19963251
[TBL] [Abstract][Full Text] [Related]
14. Evolution and outcomes of 3 MHz high intensity focused ultrasound therapy for localized prostate cancer during 15 years.
Thüroff S; Chaussy C
J Urol; 2013 Aug; 190(2):702-10. PubMed ID: 23415962
[TBL] [Abstract][Full Text] [Related]
15. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
16. Comparison of biochemical failure definitions for predicting local cancer recurrence following cryoablation of the prostate.
Pitman M; Shapiro EY; Hruby GW; Truesdale MD; Cheetham PJ; Saad S; Katz AE
Prostate; 2012 Dec; 72(16):1802-8. PubMed ID: 22618738
[TBL] [Abstract][Full Text] [Related]
17. Primary Whole-gland Cryoablation for Prostate Cancer: Biochemical Failure and Clinical Recurrence at 5.6 Years of Follow-up.
Oishi M; Gill IS; Ashrafi AN; Lin-Brande M; Nassiri N; Shin T; Bove A; Cacciamani GE; Ukimura O; Bahn DK; Abreu ALC
Eur Urol; 2019 Feb; 75(2):208-214. PubMed ID: 30274702
[TBL] [Abstract][Full Text] [Related]
18. Salvage prostate cryoablation: initial results from the cryo on-line data registry.
Pisters LL; Rewcastle JC; Donnelly BJ; Lugnani FM; Katz AE; Jones JS
J Urol; 2008 Aug; 180(2):559-63; discussion 563-4. PubMed ID: 18554664
[TBL] [Abstract][Full Text] [Related]
19. Correlation of prostate-specific antigen nadir and biochemical failure after high-intensity focused ultrasound of localized prostate cancer based on the Stuttgart failure criteria - analysis from the @-Registry.
Ganzer R; Robertson CN; Ward JF; Brown SC; Conti GN; Murat FJ; Pasticier G; Rebillard X; Thuroff S; Wieland WF; Blana A
BJU Int; 2011 Oct; 108(8 Pt 2):E196-201. PubMed ID: 21332907
[TBL] [Abstract][Full Text] [Related]
20. Primary whole-gland ablation for localized prostate cancer with high-intensity focused ultrasound: The important predictors of biochemical recurrence.
Chen PY; Chiang PH; Liu YY; Chuang YC; Cheng YT
Int J Urol; 2018 Jun; 25(6):615-620. PubMed ID: 29756298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
